May 10, 2022 - Portal Instruments has been featured in Fierce Pharma. "Gerresheimer invests in Portal's needle-free drug delivery, teeing Takeda partner up to advance tech", showcases Gerresheimer's agreement with Portal to support the development of the needle-free drug delivery platform.
May 10, 2022 -Yesterday, Fierce Pharma published an article showcasing Gerresheimer's investment into Portal Instruments. The article titled, "Gerresheimer invests in Portal's needle-free drug delivery, teeing Takeda partner up to advance tech", showcases Gerresheimer's agreement with Portal to support the development of the needle-free drug delivery platform.
Read the full article here:
October 2019 - Drug development is a costly, long, and uncertain endeavor. The cost of taking a drug from preclinical research through market approval is $2.6 billion according to a recent study by the Tufts Center for the Study of Drug Development.
March 27th, 2020 Portal’s mission is to improve the experience for patients on life-changing therapies and that mission remains in the forefront of our minds as we, like everyone else, navigate these unchartered waters with the COVID-19 pandemic.
October 1, 2023 - In a special feature by Drug Development and Delivery, Dr. Anquetil, PHD, MBA, CEO and Founder of Portal Instruments, explains how PRIME not only prioritizes patient comfort and compliance but also aligns with environmental sustainability.
Please fill out the details below and we will get back to you shortly.